Literature DB >> 14707447

Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer.

Xian-Zhong Ding1, Wei-Gang Tong, Thomas E Adrian.   

Abstract

Pancreatic carcinoma is characterized by poor prognosis and lack of response to conventional therapy. The reasons for this are not fully understood. We have reported that inhibition of 5-lipoxygenase abolished proliferation and induced apoptosis in pancreatic cancer cells while the 5-lipoxygenase metabolite, 5(S)-hydroxyeicosatetraenoic acid [5(S)-HETE] stimulated pancreatic cancer cell proliferation. The current study was designed to investigate the underlying mechanisms for 5(S)-HETE-stimulated proliferation of pancreatic cells. Two human pancreatic cancer cell lines, PANC-1 and HPAF, were used. Cell proliferation was monitored by thymidine incorporation and cell counting. Phosphorylation of P42/44(MAPK) (mitogen activated protein kinase, ERK), MEK (MAPK/ERK kinase), P38 kinase, JNK/SAPK (c-Jun N-terminal kinase/ stress-activated protein kinase), AKT and tyrosine residues of intracellular proteins was measured by Western blot using their corresponding phospho-specific antibodies. The results showed that (1) 5(S)-HETE markedly stimulated pancreatic cancer cell proliferation in a time- and concentration-dependent manner; (2) 5(S)-HETE induced tyrosine phosphorylation of multiple intracellular proteins while the tyrosine kinase inhibitor, genestein, blocked 5(S)-HETE-stimulated cell proliferation; (3) 5(S)-HETE significantly stimulated both MEK and P42/44(MAPK) phosphorylation and the MEK inhibitors, PD098059 and U0126, inhibited 5(S)-HETE-stimulated proliferation in these two cell lines; (4) 5(S)-HETE also stimulated P38 kinase phosphorylation but the P38 inhibitor, SB203580, did not effect 5(S)-HETE-stimulated cell proliferation; (5) 5(S)-HETE markedly stimulated AKT phosphorylation while the phosphatidylinositide-3 (PI3)-kinase inhibitor, wortmannin, blocked 5(S)-HETE-stimulated cell proliferation; (6) phosphorylation of JNK/SAPK was not induced by 5(S)-HETE, and (7) the general protein kinase C (PKC) inhibitor, GF109203X, did not affect 5(S)-HETE-stimulated cancer cell proliferation. These findings suggest that intracellular tyrosine kinases, MEK/ERK and PI3 kinase/AKT pathways are involved in 5(S)-HETE-stimulated pancreatic cancer cell proliferation but P38 kinase, JNK/SAPK and PKC are not involved in this mitogenic effect. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707447     DOI: 10.1159/000074640

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  13 in total

Review 1.  Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.

Authors:  Lawrence M Knab; Paul J Grippo; David J Bentrem
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes.

Authors:  Gary A Weisman; M Wang; Q Kong; N E Chorna; J T Neary; Grace Y Sun; Fernando A González; C I Seye; L Erb
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

3.  5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation.

Authors:  Alfonso Catalano; Sabrina Rodilossi; Paola Caprari; Vincenzo Coppola; Antonio Procopio
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

4.  The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.

Authors:  Neelam Sharma-Walia; Karthic Chandran; Kinjan Patel; Mohanan Valiya Veettil; Alexandru Marginean
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

5.  5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity.

Authors:  A S Fischer; J Metzner; S D Steinbrink; S Ulrich; C Angioni; G Geisslinger; D Steinhilber; T J Maier
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Hydroxyeicosatetraenoic acids in patients with pancreatic cancer: a preliminary report.

Authors:  Tomasz Bodnarczuk; Anna Deskur; Katarzyna Dolegowska; Barbara Dolegowska; Teresa Starzynska; Wojciech Blogowski
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

7.  A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.

Authors:  Junan Li; Jiuxiang Zhu; W Scott Melvin; Tanios S Bekaii-Saab; Ching-Shih Chen; Peter Muscarella
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

8.  Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.

Authors:  Nicolas T Kummer; Theodore S Nowicki; Jean P Azzi; Ismael Reyes; Codrin Iacob; Suqing Xie; Ismatun Swati; Zbigniew Darzynkiewicz; Katherine H Gotlinger; Nina Suslina; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  J Cell Biochem       Date:  2012-06       Impact factor: 4.429

9.  Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.

Authors:  Joanna M Poczobutt; Teresa T Nguyen; Dwight Hanson; Howard Li; Trisha R Sippel; Mary C M Weiser-Evans; Miguel Gijon; Robert C Murphy; Raphael A Nemenoff
Journal:  J Immunol       Date:  2015-12-11       Impact factor: 5.422

10.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.